Table 5. Comparison of plasma cytokine levels in patients included in the study categorized according to 3-month survival.
| Variables | Alive (n = 37) | Dead (n = 15) | P | Mortality AUCROC (95% IC) |
|---|---|---|---|---|
| VCAM-1 (ng/mL) | 1263 (1072–2244) | 2942 (1803–3471) | 0.001 | 0.807 (0.690–0.925) |
| ICAM-1 (ng/mL) | 1315 (978–1897) | 2633 (1704–3178) | 0.001 | 0.791 (0.667–0.915) |
| GM-CSF (pg/mL) | 46 (42–52) | 41 (40–43) | 0.013 | 0.721 (0.557–0.884) |
| MIP-1α (pg/mL) | 4.2 (3.2–6.2) | 6.0 (4.9–17.01) | 0.028 | 0.695 (0.540–0.851) |
| IP-10 (pg/mL) | 41 (29–72) | 64 (49–106) | 0.040 | 0.683 (0.523–0.842) |
| RANTES (pg/mL) | 287 (85–895) | 125 (71–280) | 0.077 | 0.658 (0.499–0.816) |
| IL-2 (pg/mL) | 19 (14.6–36) | 15 (4.0–27) | 0.077 | 0.658 (0.479–0.836) |
| IL-1β (pg/mL) | 4.0 (2.6–5.9) | 3.2 (1.8–3.7) | 0.108 | 0.643 (0.483–0.804) |
| MPC-1 (pg/mL) | 17.8 (12.4–33.9) | 27.6 (17.5–48.4) | 0.138 | 0.632 (0.458–0.807) |
| IL-7 (pg/mL) | 1.6 (1.5–1.8) | 1.5 (1.5–1.6) | 0.146 | 0.630 (0.471–0.789) |
| PDGF-BB (pg/mL) | 84 (38–272) | 46 (16–93) | 0.183 | 0.619 (0.456–0.782) |
| IL-13 (pg/mL) | 5.0 (4.5–6.3) | 4.6 (4.5–5.1) | 0.229 | 0.607 (0.450–0.764) |
| Fractalkine (pg/mL) | 5.4 (3.8–7.3) | 6.3 (5.1–7.6) | 0.233 | 0.606 (0.456–0.757) |
| Eotaxin (pg/mL) | 43 (33–58) | 44 (32–81) | 0.486 | 0.562 (0.367–0.757) |
| IL-10 (pg/mL) | 2.1 (0.5–4.4) | 1.3 (0.1–4.8) | 0.525 | 0.557 (0.382–0.731) |
| VEGF-A (pg/mL) | 140 (55–221) | 163 (87–224) | 0.538 | 0.555 (0.391–0.719) |
| MIP-1β (pg/mL) | 122 (91–160) | 116 (85–159) | 0.754 | 0.528 (0.355–0.701) |
| G-CSF (pg/mL) | 38 (25–69) | 42 (15–83) | 1.000 | 0.500 (0.312–0.688) |
| IL-6 (pg/mL) | 47 (21–100) | 45 (25–117) | 0.976 | 0.497 (0.323–0.672) |
| IFN-γ (pg/mL) | 11 (8–28) | 15 (4.7–18) | 0.777 | 0.475 (0.287–0.662) |
AUCROC, area under the receiver-operating characteristic curves.
Values are expressed as median and IQR (in brackets).
The 3 patients transplanted during the 3-month follow-up period were excluded from the analysis.